Rahmannia Maryam, Poudineh Mohadeseh, Mirzaei Roya, Aalipour Mohammad Amin, Shahidi Bonjar Amir Hashem, Goudarzi Mehdi, Kheradmand Ali, Aslani Hamid Reza, Sadeghian Majid, Nasiri Mohammad Javad, Sechi Leonardo Antonio
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Scientist of Dental Materials and Restorative Dentistry, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gut Pathog. 2024 Sep 8;16(1):46. doi: 10.1186/s13099-024-00634-8.
Depression and anxiety are pervasive mental health disorders with substantial global burdens. Probiotics, live microorganisms known for their health benefits, have emerged as a potential therapeutic intervention for these conditions. This systematic review and meta-analysis aim to evaluate the strain-specific effects of probiotics on relieving depressive and anxiety symptoms while elucidating underlying mechanisms.
EMBASE, Cochrane CENTRAL and PubMed/Medline were systematically queried to identify studies released until May 15, 2024. Randomized Controlled Trials (RCTs) that employed standardized assessment tools for depression and anxiety namely Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HAMD), Depression Anxiety Stress Scales (DASS), or Montgomery-Asberg Depression Rating Scale (MADRS) were included.
12 RCTs involving 707 participants were included. Seven RCTs utilizing the BDI questionnaire demonstrated a significant decrease in depressive symptoms favoring probiotics containing strains such as Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus salivarius, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium breve, and Bifidobacterium longum (MD: -2.69, CI95%: -4.22/-1.16, p value: 0.00). Conversely, RCTs using HAMD showed a non-significant reduction in depressive symptoms (MD: -1.40, CI95%: -3.29/0.48, p value: 0.14). RCTs employing DASS and MADRS scales also showed no significant differences.
This meta-analysis offers valuable insights into the strain-specific effects of probiotics containing Lactobacillus and Bifidobacterium species on depressive and anxiety symptoms. While our findings suggest a significant reduction in depressive symptoms based on the BDI scale favoring probiotics, the lack of significant effects observed on the HAMD, DASS, and MADRS scales underscores the complexity inherent in these conditions. It is imperative to acknowledge the mixed results across different measurement scales, indicating the need for cautious interpretation. Therefore, we advocate for a nuanced understanding of probiotics' impacts on various dimensions of mood, emphasizing the necessity for further research.
抑郁症和焦虑症是普遍存在的心理健康障碍,给全球带来了沉重负担。益生菌是一种以有益健康而闻名的活微生物,已成为治疗这些疾病的潜在干预手段。本系统评价和荟萃分析旨在评估益生菌对缓解抑郁和焦虑症状的菌株特异性作用,并阐明其潜在机制。
系统检索了EMBASE、Cochrane CENTRAL和PubMed/Medline,以确定截至2024年5月15日发布的研究。纳入使用标准化抑郁和焦虑评估工具(即贝克抑郁量表(BDI)、汉密尔顿抑郁评定量表(HAMD)、抑郁焦虑压力量表(DASS)或蒙哥马利-阿斯伯格抑郁评定量表(MADRS))的随机对照试验(RCT)。
纳入了12项涉及707名参与者的RCT。七项使用BDI问卷的RCT显示,含有嗜酸乳杆菌、副干酪乳杆菌、干酪乳杆菌、植物乳杆菌、唾液乳杆菌、双歧双歧杆菌、双歧乳酸杆菌、短双歧杆菌和长双歧杆菌等菌株的益生菌,抑郁症状显著减轻(MD:-2.69,CI95%:-4.22/-1.16,p值:0.00)。相反,使用HAMD的RCT显示抑郁症状减轻不显著(MD:-1.40,CI95%:-3.29/0.48,p值:0.14)。使用DASS和MADRS量表的RCT也未显示出显著差异。
本荟萃分析为含有乳酸杆菌和双歧杆菌属的益生菌对抑郁和焦虑症状的菌株特异性作用提供了有价值的见解。虽然我们的研究结果表明,基于BDI量表,益生菌可显著减轻抑郁症状,但在HAMD、DASS和MADRS量表上未观察到显著效果,这凸显了这些疾病固有的复杂性。必须认识到不同测量量表的结果参差不齐,这表明需要谨慎解读。因此,我们主张对益生菌对情绪各个维度的影响有细致入微的理解,强调进一步研究的必要性。